Why Bausch Health Shares Are Trading Higher Today

Loading...
Loading...
  • Bausch Health Companies Inc BHC reported Q4 revenues of $2.2 billion, flat Y/Y, up 4% organic basis, above the consensus estimate of $2.14 billion.
  • "2022 was a transformative year for Bausch Health, as we executed our strategic priorities," said Thomas Appio, CEO of Bausch Health. "Since completing the initial public offering of Bausch + Lomb last May, we have made significant progress in de-levering our balance sheet, reducing our principal debt net of unrestricted cash by $3.2 billion. 
  • The company reported an EPS loss of ($1.13) compared with an income of $0.19 last year.
  • Adjusted EBITDA fell to $823 million from $909 million.
  • Related: Bausch Health Investors Request Blocking Eye-Care Business Spinoff, Alleging Protection From Lawsuits.
  • Guidance: Bausch Health is not providing consolidated full-year guidance, as Bausch + Lomb has not provided full-year guidance. 
  • Bausch Health (excl. B+L) expects FY23 sales of $4.45 - $4.6 billion and Adjusted EBITDA of $2.3 - $2.4 billion.
  • Price Action: BHC shares are up 11.1% at $9.60 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...